Want to join the conversation?
$MRK said an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped, and that patients receiving chemotherapy in Keynote-024 be offered the opportunity to receive Keytruda. $MRK is advancing five registration-enabling studies for non-small cell lung cancer with Keytruda as a monotherapy and in combination.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.